Immunoprecise Stock Today

IPA -  USA Stock  

USD 5.30  0.15  2.75%

Market Performance
3 of 100
Odds Of Distress
Less than 28
Immunoprecise Antibodies is trading at 5.30 as of the 28th of May 2022, a -2.75 percent decrease since the beginning of the trading day. The stock's open price was 5.45. Immunoprecise Antibodies has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Immunoprecise Antibodies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of June 2020 and ending today, the 28th of May 2022. Please note, there could be an existing legal relationship between Immunoprecise Antibodies (IPA) and Interpharm Holdings (IPAH). Click here to learn more.
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. The company has 19.43 M outstanding shares of which 291.31 K shares are currently shorted by investors with about 7.78 days to cover. More on Immunoprecise Antibodies
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Immunoprecise Antibodies Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Immunoprecise Antibodies' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunoprecise Antibodies or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Immunoprecise Antibodies has very high historical volatility over the last 90 days
Immunoprecise Antibodies was previously known as IMMUNOPRECISE ANTIBODIES LTD and was traded on NASDAQ Exchange under the symbol IPATF.
The company reported the last year's revenue of 19 M. Reported Net Loss for the year was (17.1 M) with profit before taxes, overhead, and interest of 11.4 M.
Immunoprecise Antibodies has about 32.99 M in cash with (8.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.7.
Immunoprecise Antibodies has a poor financial position based on the latest SEC disclosures
Latest headline from Biotech Recovery Accelerates These Companies Benefit - Digital Journal
Immunoprecise Antibodies Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Immunoprecise Antibodies SEC Filings
Immunoprecise Antibodies SEC Filings Security & Exchange Commission EDGAR Reports
Older SymbolIPATF
Related EntityIPAH (Interpharm Holdings)
Thematic Classification
Currently Active Investing Idea (view all)
Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Immunoprecise Antibodies report their recommendations after researching Immunoprecise Antibodies' financial statements, talking to executives and customers, or listening in on Immunoprecise Antibodies' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Immunoprecise Antibodies. The Immunoprecise consensus assessment is calculated by taking the average forecast from all of the analysts covering Immunoprecise Antibodies.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Immunoprecise Antibodies based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Immunoprecise Antibodies financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares18.2 M18.9 M
Sufficiently Down
Slightly volatile
Weighted Average Shares Diluted18.2 M18.9 M
Sufficiently Down
Slightly volatile
Total Assets64.2 M77 M
Fairly Down
Slightly volatile
Total Liabilities9.3 MM
Sufficiently Up
Current Assets60.6 M56.2 M
Significantly Up
Slightly volatile
Current Liabilities5.9 M5.5 M
Notably Up
Slightly volatile
Total Debt4.2 MM
Notably Up
Slightly volatile
Gross Margin0.720.74
Fairly Down
Slightly volatile
Asset Turnover0.360.34
Notably Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Immunoprecise Antibodies' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Immunoprecise Antibodies' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Immunoprecise Antibodies' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immunoprecise Antibodies' financial leverage. It provides some insight into what part of Immunoprecise Antibodies' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Immunoprecise Antibodies' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Immunoprecise Antibodies deploys its capital and how much of that capital is borrowed.
Immunoprecise Antibodies cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 2.81 M in debt with debt to equity (D/E) ratio of 0.06, which may show that the company is not taking advantage of profits from borrowing. Immunoprecise Antibodies has a current ratio of 5.57, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Immunoprecise Antibodies until it has trouble settling it off, either with new capital or with free cash flow. So, Immunoprecise Antibodies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immunoprecise Antibodies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immunoprecise to invest in growth at high rates of return. When we think about Immunoprecise Antibodies' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

Immunoprecise Antibodies (IPA) is traded on NASDAQ Exchange in USA. It is located in 3204–4464 Markham Street and employs 73 people. Immunoprecise Antibodies was previously known as IMMUNOPRECISE ANTIBODIES LTD and was traded on NASDAQ Exchange under the symbol IPATF. Immunoprecise Antibodies is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with total capitalization of 102.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunoprecise Antibodies's market, we take the total number of its shares issued and multiply it by Immunoprecise Antibodies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Immunoprecise Antibodies runs under Healthcare sector within Biotechnology industry. The entity has 19.43 M outstanding shares of which 291.31 K shares are currently shorted by investors with about 7.78 days to cover. Immunoprecise Antibodies has about 32.99 M in cash with (8.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.7.
Check Immunoprecise Antibodies Probability Of Bankruptcy
Immunoprecise Antibodies secures a total of 19.43 Million outstanding shares. Immunoprecise Antibodies retains 6.92 (percent) if its outstanding shares held by insiders and 6.92 (percent) owned by outside corporations . Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Immunoprecise Ownership Details

Immunoprecise Stock Price Odds Analysis

What are Immunoprecise Antibodies' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Immunoprecise Antibodies jumping above the current price in 90 days from now is about 28.75%. The Immunoprecise Antibodies probability density function shows the probability of Immunoprecise Antibodies stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 1.0079. This usually indicates Immunoprecise Antibodies market returns are sensitive to returns on the market. As the market goes up or down, Immunoprecise Antibodies is expected to follow. Additionally, the company has an alpha of 0.2311, implying that it can generate a 0.23 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 5.3HorizonTargetOdds Above 5.3
71.14%90 days
Based on a normal probability distribution, the odds of Immunoprecise Antibodies to move above the current price in 90 days from now is about 28.75 (This Immunoprecise Antibodies probability density function shows the probability of Immunoprecise Stock to fall within a particular range of prices over 90 days) .

Immunoprecise Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Immunoprecise Antibodies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunoprecise Antibodies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunoprecise Antibodies' value.
InstituionSecurity TypeTotal SharesValue
Ingalls Snyder LlcCommon Shares932.2 K4.8 M
Citadel Advisors LlcCall Options296.6 K1.5 M
Bank Of MontrealCommon Shares140.5 K718 K
Susquehanna International Group LlpPut Options36.1 K186 K
View Immunoprecise Antibodies Diagnostics

Immunoprecise Antibodies Historical Income Statement

Immunoprecise Antibodies Income Statement is one of the three primary financial statements used for reporting Immunoprecise's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Immunoprecise Antibodies revenue and expense. Immunoprecise Antibodies Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Immunoprecise Antibodies Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 7.33 Million. The current year Interest Expense is expected to grow to about 596.1 K, whereas Consolidated Income is forecasted to decline to (9.1 M). View More Fundamentals

Immunoprecise Stock Against Markets

Picking the right benchmark for Immunoprecise Antibodies stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Immunoprecise Antibodies stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Immunoprecise Antibodies is critical whether you are bullish or bearish towards Immunoprecise Antibodies at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunoprecise Antibodies without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Suggestion Now


Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module

Investing Immunoprecise Antibodies

You need to understand the risk of investing before taking a position in Immunoprecise Antibodies. The danger of trading Immunoprecise Antibodies is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Immunoprecise Antibodies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Immunoprecise Antibodies. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Immunoprecise Antibodies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Risk vs Return Analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Money Managers
Screen money managers from public funds and ETFs managed around the world
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
CEO Directory
Screen CEOs from public companies around the world
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Global Correlations
Find global opportunities by holding instruments from different markets
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.